Chardan Capital restated their buy rating on shares of Forte Biosciences (NASDAQ:FBRX – Free Report) in a research note released on Monday morning, Benzinga reports. The brokerage currently has a $3.00 target price on the stock. Chardan Capital also issued estimates for Forte Biosciences’ FY2024 earnings at ($0.87) EPS and FY2025 earnings at ($0.61) EPS.
Separately, Brookline Capital Management began coverage on shares of Forte Biosciences in a report on Thursday, May 30th. They set a buy rating and a $4.00 target price on the stock.
View Our Latest Analysis on Forte Biosciences
Forte Biosciences Trading Down 2.8 %
Forte Biosciences (NASDAQ:FBRX – Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.11). As a group, equities research analysts forecast that Forte Biosciences will post -0.59 EPS for the current fiscal year.
Hedge Funds Weigh In On Forte Biosciences
An institutional investor recently bought a new position in Forte Biosciences stock. Cable Car Capital LLC bought a new position in shares of Forte Biosciences, Inc. (NASDAQ:FBRX – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 2,031,987 shares of the company’s stock, valued at approximately $1,670,000. Forte Biosciences comprises approximately 1.9% of Cable Car Capital LLC’s holdings, making the stock its 18th biggest holding. Cable Car Capital LLC owned about 5.59% of Forte Biosciences as of its most recent SEC filing. 77.63% of the stock is owned by hedge funds and other institutional investors.
About Forte Biosciences
Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.
Recommended Stories
- Five stocks we like better than Forte Biosciences
- Conference Calls and Individual Investors
- Advance Auto Parts Eyes Long-Term Growth Despite Q2 Hurdles
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Toll Brothers Stock Up on Q3 Beat: Luxury Homes Drive Growth
- ESG Stocks, What Investors Should Know
- 4 No-Brainer Stocks to Hold This Fall for Steady Gains
Receive News & Ratings for Forte Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forte Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.